FDA Approved Camzyos for Pediatric Heart Condition

The FDA has authorized the use of Camzyos for children with symptomatic obstructive hypertrophic cardiomyopathy.

Updated on Sept. 30, 2026 in Heart Disease

Bold flat-color editorial illustration of a stylized heart model in navy and cream, signifying medical regulatory policy. — The FDA has authorized the use of the drug Camzyos for pediatric patients diagnosed with symptomatic obstructive hypertrophic cardiomyopathy. AI Illustration. Upload story photo >

The FDA has granted approval for Camzyos to treat pediatric patients weighing at least 30 kg who have symptomatic obstructive hypertrophic cardiomyopathy. This decision extends the availability of the drug, which was previously limited to adult use.

Why it matters

Obstructive hypertrophic cardiomyopathy causes a thickened heart muscle that narrows the left ventricular outflow tract, potentially hindering functional capacity. This approval provides a new treatment option for younger patients to help manage these symptoms.

A Phase 3 study of 44 patients aged 12 to 18 years evaluated the medication over 28 weeks. Common side effects occurring in more than 5% of participants included dizziness and fainting.

The players

FDA

The Food and Drug Administration is the federal agency responsible for protecting public health by ensuring the safety, efficacy, and security of human drugs.

The details

Patients in the study received either Camzyos or a placebo once daily to measure changes in pressure within the left ventricular outflow tract while bearing down. The drug carries a boxed warning for heart failure risk and is only available through a restricted Risk Evaluation and Mitigation Strategy program.

The FDA initially approved Camzyos for adult patients in 2022.
The agency approved the drug for pediatric use on September 30, 2026.

Health Landscape

This approval follows the established framework of the FDA's Risk Evaluation and Mitigation Strategy program to ensure safe drug administration. It marks a significant expansion of care options for pediatric heart disease patients since the drug first received adult approval.

Families may discuss this new treatment option with their pediatric cardiologists to determine if it is appropriate for their specific diagnosis. Due to the boxed warning for heart failure, patients must adhere to the mandatory Risk Evaluation and Mitigation Strategy protocols.

The takeaway

Patients and caregivers should maintain regular communication with medical providers to monitor for side effects like dizziness. This approval represents a targeted effort to provide orphan drug therapies for younger populations with rare cardiac conditions.